Akari Therapeutics, Plc Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for the quarter ending 2026-06-30 was $3.04M, a 387.94% increase year-over-year.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for the quarter ending 2025-06-30 was $622.00K.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for the quarter ending 2015-12-31 was $0.00.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for fiscal 2025 was $622.00K, a 129.52% increase from fiscal 2024.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for fiscal 2024 was $271.00K.
- Akari Therapeutics, Plc stock issued during period, value, issued for services for fiscal 2012 was $25.00K.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-06-30 | $3.04M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $622.00K 10-K · filed 2026-03-30 | |
| 2025-06-30 | $622.00K 10-Q · filed 2025-11-13 | |
| 2024-12-31 | $271.00K 10-K · filed 2026-03-30 | |
| 2015-12-31 | $0.00 derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | $750.00K 20-F · filed 2018-07-18 |
| 2014-12-31 | $56.00K 10-Q · filed 2015-05-12 | |
| 2012-12-31 | $25.00K 10-K · filed 2015-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |